US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Maze Therapeutics

45.03

+1.082.46%

Post-market: 45.030.00000.00%16:49 EST

Volume:663.46K

Turnover:29.74M

Market Cap:2.15B

PE:-21.19

High:46.18

Open:44.29

Low:42.79

Close:43.95

52wk High:49.25

52wk Low:6.71

Shares:47.85M

Float Shares:20.43M

Volume Ratio:0.94

T/O Rate:3.25%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.1250

EPS(LYR):1.25

ROE:-52.69%

ROA:-27.37%

PB:5.68

PE(LYR):36.02

Loading ...

Overview Company News Filings

Maze Therapeutics files automatic mixed securities shelf

Maze Therapeutics Secures New $200 Million Loan Facility

Maze Therapeutics Inc Files for Mixed Shelf; Size Not Disclosed - SEC Filing

THOMSON REUTERS

Maze Therapeutics : Sales Agreement Prospectus Supplement Covering Offering of up to $200 Mln of Common Stock

THOMSON REUTERS

Maze Therapeutics Inc - Hercules Term Loan Facility up to $200 Mln - SEC Filing

THOMSON REUTERS

Maze Therapeutics Secures Up to $200 Million Term Loan Facility from Hercules Capital

Maze Therapeutics President and CMO Harold Bernstein Reports Disposal of Common Shares

Maze Therapeutics to Present at Guggenheim Emerging Outlook: Biotech Summit 2026

Analysts Offer Insights on Healthcare Companies: Olema Pharmaceuticals (OLMA) and Maze Therapeutics, Inc. (MAZE)

Maze Therapeutics CSBO Atul Dandekar Reports Disposal of Common Shares

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Maze Therapeutics, Inc. (MAZE), Adagene (ADAG) and Johnson & Johnson (JNJ)

Maze Therapeutics Inc : JP Morgan Raises Target Price to $52 From $42

THOMSON REUTERS

Buy Rating on Maze Therapeutics: Attractive Risk‑Reward Driven by Differentiated APOL1 Kidney Disease Therapy MZE829 and Raised $46 Target

Maze Therapeutics price target raised to $46 from $37 at BTIG

Maze Therapeutics Showcases Pipeline Advancements in Kidney and Metabolic Diseases

Maze Therapeutics Is Maintained at Buy by BTIG

Maze Therapeutics Showcases Pipeline Advancements in Kidney and Metabolic Disease Therapies

Maze Therapeutics President, R&D & CMO Harold Bernstein Reports Disposal of Common Shares

Maze Therapeutics Director Makes Major Insider Move With High-Value Stock Sale

Maze Therapeutics Director Catherine A. Sohn Reports Disposal of Common Shares

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/MAZE/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MAZE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MAZE\",,,,,undefined,":{"symbol":"MAZE","market":"US","secType":"STK","nameCN":"Maze Therapeutics","latestPrice":45.03,"timestamp":1770411600000,"preClose":43.95,"halted":0,"volume":663460,"hourTrading":{"tag":"盘后","latestPrice":45.03,"preClose":45.03,"latestTime":"16:49 EST","volume":395,"amount":17835.03,"timestamp":1770414545825,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.024573378839590404,"floatShares":20434300,"shares":47850886,"eps":-2.125,"marketStatus":"Market Closed","change":1.08,"latestTime":"02-06 16:00:00 EST","open":44.29,"high":46.18,"low":42.79,"amount":29736902.17932,"amplitude":0.077133,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-2.125,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"listingDate":1738299600000,"exchange":"NASDAQ","adjPreClose":43.95,"preHourTrading":{"tag":"盘前","latestPrice":44.9,"preClose":43.95,"latestTime":"08:41 EST","volume":179,"amount":7979.119036,"timestamp":1770385266689,"change":0.95,"changeRate":0.021615,"amplitude":0.021615},"postHourTrading":{"tag":"盘后","latestPrice":45.03,"preClose":45.03,"latestTime":"16:49 EST","volume":395,"amount":17835.03,"timestamp":1770414545825,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.9398042213199315,"impliedVol":1.1114,"impliedVolPercentile":0.9293},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MAZE\",,,,,undefined,":{"symbol":"MAZE","floatShares":20434300,"roa":"-27.37%","roe":"-52.69%","lyrEps":1.25,"volumeRatio":0.9398042213199315,"shares":47850886,"dividePrice":0,"high":46.18,"amplitude":0.077133,"preClose":43.95,"low":42.79,"week52Low":6.71,"pbRate":"5.68","week52High":49.25,"institutionHeld":0,"latestPrice":45.03,"eps":-2.125,"divideRate":0,"volume":663460,"delay":0,"ttmEps":-2.125,"open":44.29,"prevYearClose":41.43,"prevWeekClose":43.58,"prevMonthClose":43.58,"prevQuarterClose":41.43,"fiveDayClose":43.58,"twentyDayClose":38.95,"sixtyDayClose":30.49},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MAZE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-06","symbol":"MAZE","fiscalQuarterEnding":"2025/09","expectedEps":-0.74,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"post","actualEps":-0.66},{"market":"US","date":"2025-08-12","symbol":"MAZE","fiscalQuarterEnding":"2025/06","expectedEps":-0.79,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"post","actualEps":-0.77},{"market":"US","date":"2025-05-14","symbol":"MAZE","fiscalQuarterEnding":"2025/03","expectedEps":-0.76,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"post","actualEps":-1.15},{"market":"US","date":"2025-03-31","symbol":"MAZE","fiscalQuarterEnding":"2024/12","expectedEps":-7.6,"name":null,"time":"","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"","actualEps":-18.32}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MAZE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MAZE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":10,"updateTime":1770181200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MAZE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MAZE","date":"2026-02-06","current":-21.190588,"percent":0.035156,"low":-18.365588,"twenty":-13.567798,"median":6.791906,"eighty":10.126096,"high":14.99285,"avg":-0.472826,"sd":11.275418,"marketCap":2114849563},"quantilePoints":[{"date":"2025-01-31","current":12.681398,"twenty":12.46124,"median":12.543799,"eighty":12.626358,"marketCap":700431648},{"date":"2025-02-07","current":10.303636,"twenty":10.343265,"median":11.88881,"eighty":12.594654,"marketCap":569100714},{"date":"2025-02-14","current":8.972089,"twenty":9.94063,"median":10.40271,"eighty":12.302722,"marketCap":495555390},{"date":"2025-02-21","current":9.645788,"twenty":9.645788,"median":10.220414,"eighty":11.88881,"marketCap":532765822},{"date":"2025-02-28","current":10.081711,"twenty":9.495197,"median":10.081711,"eighty":10.604819,"marketCap":556843160},{"date":"2025-03-07","current":9.29705,"twenty":9.29705,"median":9.788453,"eighty":10.501783,"marketCap":513503951},{"date":"2025-03-14","current":8.956237,"twenty":8.972089,"median":9.582381,"eighty":10.303636,"marketCap":494679851},{"date":"2025-03-21","current":9.479345,"twenty":8.972089,"median":9.534826,"eighty":10.271932,"marketCap":523572656},{"date":"2025-03-28","current":8.93246,"twenty":8.956237,"median":9.495197,"eighty":10.168896,"marketCap":493366542},{"date":"2025-04-04","current":7.814885,"twenty":8.89283,"median":9.443679,"eighty":10.137192,"marketCap":408179251},{"date":"2025-04-11","current":6.372653,"twenty":8.695317,"median":9.384234,"eighty":10.081711,"marketCap":332850033},{"date":"2025-04-17","current":6.858987,"twenty":8.362362,"median":9.29705,"eighty":9.98026,"marketCap":358251746},{"date":"2025-04-25","current":6.456504,"twenty":7.783022,"median":9.224877,"eighty":9.897831,"marketCap":337229638},{"date":"2025-05-02","current":8.879789,"twenty":7.580103,"median":8.972089,"eighty":9.731387,"marketCap":463800243},{"date":"2025-05-09","current":8.40184,"twenty":7.63209,"median":8.956237,"eighty":9.655299,"marketCap":438836491},{"date":"2025-05-16","current":7.799992,"twenty":7.63958,"median":8.89283,"eighty":9.626766,"marketCap":405123785},{"date":"2025-05-23","current":8.575775,"twenty":7.65241,"median":8.850167,"eighty":9.590307,"marketCap":445417178},{"date":"2025-05-30","current":10.26226,"twenty":7.715941,"median":8.87535,"eighty":9.631522,"marketCap":533011510},{"date":"2025-06-06","current":11.248853,"twenty":7.782471,"median":8.89283,"eighty":9.769431,"marketCap":584254194},{"date":"2025-06-13","current":11.425934,"twenty":7.799992,"median":8.956237,"eighty":10.149874,"marketCap":593451599},{"date":"2025-06-20","current":9.494909,"twenty":7.805949,"median":9.034945,"eighty":10.238649,"marketCap":493156089},{"date":"2025-06-27","current":10.742908,"twenty":7.871903,"median":9.097801,"eighty":10.238649,"marketCap":557975894},{"date":"2025-07-03","current":9.697287,"twenty":7.967493,"median":9.217791,"eighty":10.255514,"marketCap":503667409},{"date":"2025-07-11","current":13.188311,"twenty":8.01948,"median":9.285161,"eighty":10.297295,"marketCap":684987676},{"date":"2025-07-18","current":14.385715,"twenty":8.08904,"median":9.384234,"eighty":10.584212,"marketCap":747179651},{"date":"2025-07-25","current":13.871337,"twenty":8.197097,"median":9.417731,"eighty":10.84241,"marketCap":720463380},{"date":"2025-08-01","current":12.437825,"twenty":8.267679,"median":9.479345,"eighty":11.289329,"marketCap":646008198},{"date":"2025-08-08","current":11.231989,"twenty":8.274387,"median":9.503122,"eighty":11.660356,"marketCap":583378251},{"date":"2025-08-15","current":-4.846264,"twenty":8.197097,"median":9.495197,"eighty":11.50014,"marketCap":585409301},{"date":"2025-08-22","current":-4.802702,"twenty":7.843394,"median":9.46183,"eighty":11.412442,"marketCap":580147195},{"date":"2025-08-29","current":-5.180239,"twenty":7.675693,"median":9.408012,"eighty":11.34667,"marketCap":625752114},{"date":"2025-09-05","current":-5.459761,"twenty":7.605258,"median":9.384234,"eighty":11.299448,"marketCap":659517295},{"date":"2025-09-12","current":-9.002797,"twenty":7.051844,"median":9.285161,"eighty":11.248853,"marketCap":1087501923},{"date":"2025-09-19","current":-8.523616,"twenty":6.791906,"median":9.217791,"eighty":11.231989,"marketCap":1029618756},{"date":"2025-09-26","current":-9.565472,"twenty":6.372653,"median":9.072896,"eighty":11.223556,"marketCap":1155470793},{"date":"2025-10-03","current":-9.619925,"twenty":-4.846264,"median":8.956237,"eighty":11.080205,"marketCap":1162048426},{"date":"2025-10-10","current":-10.440341,"twenty":-4.897086,"median":8.912645,"eighty":10.903124,"marketCap":1261151423},{"date":"2025-10-17","current":-10.327806,"twenty":-5.035032,"median":8.87091,"eighty":10.852529,"marketCap":1247557649},{"date":"2025-10-24","current":-10.854179,"twenty":-5.43435,"median":8.743704,"eighty":10.801935,"marketCap":1311141431},{"date":"2025-10-31","current":-12.059392,"twenty":-5.764695,"median":8.710535,"eighty":10.776638,"marketCap":1456726366},{"date":"2025-11-07","current":-10.301208,"twenty":-8.440123,"median":8.622163,"eighty":10.742908,"marketCap":1299301692},{"date":"2025-11-14","current":-12.147078,"twenty":-8.530877,"median":8.52824,"eighty":10.604819,"marketCap":1532123096},{"date":"2025-11-21","current":-13.570087,"twenty":-9.148004,"median":8.467465,"eighty":10.501783,"marketCap":1711608623},{"date":"2025-11-28","current":-14.401765,"twenty":-9.516102,"median":8.389744,"eighty":10.458575,"marketCap":1816509011},{"date":"2025-12-05","current":-16.252058,"twenty":-9.864597,"median":8.267679,"eighty":10.366822,"marketCap":2049888314},{"date":"2025-12-12","current":-15.096102,"twenty":-10.151143,"median":8.122944,"eighty":10.312226,"marketCap":1904086399},{"date":"2025-12-19","current":-15.496681,"twenty":-10.373183,"median":7.957431,"eighty":10.278273,"marketCap":1954611815},{"date":"2025-12-26","current":-16.053676,"twenty":-10.591356,"median":7.799992,"eighty":10.266129,"marketCap":2024866203},{"date":"2026-01-02","current":-15.805699,"twenty":-10.832398,"median":7.756189,"eighty":10.248768,"marketCap":1993588564},{"date":"2026-01-09","current":-14.859569,"twenty":-11.164921,"median":7.639287,"eighty":10.225157,"marketCap":1874252343},{"date":"2026-01-16","current":-15.187663,"twenty":-11.722514,"median":7.479482,"eighty":10.213352,"marketCap":1915635065},{"date":"2026-01-23","current":-17.625471,"twenty":-12.065201,"median":7.127309,"eighty":10.196366,"marketCap":2223118312},{"date":"2026-01-30","current":-17.167667,"twenty":-12.419472,"median":6.955415,"eighty":10.162555,"marketCap":2165374980},{"date":"2026-02-06","current":-16.767088,"twenty":-13.567798,"median":6.791906,"eighty":10.126096,"marketCap":2114849563}],"updateTime":1770585176095},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MAZE\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2609116913","title":"Maze Therapeutics files automatic mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2609116913","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609116913?lang=en_us&edition=fundamental","pubTime":"2026-02-05 06:26","pubTimestamp":1770243963,"startTime":"0","endTime":"0","summary":"17:20 EST Maze Therapeutics (MAZE) files automatic mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-mov...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maze-therapeutics-files-automatic-mixed-securities-shelf-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maze-therapeutics-files-automatic-mixed-securities-shelf-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","MAZE"],"gpt_icon":0},{"id":"2609319238","title":"Maze Therapeutics Secures New $200 Million Loan Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2609319238","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609319238?lang=en_us&edition=fundamental","pubTime":"2026-02-05 06:21","pubTimestamp":1770243708,"startTime":"0","endTime":"0","summary":"Maze Therapeutics, Inc. ( ($MAZE) ) has provided an update. On February 4, 2026, Maze Therapeutics, Inc. entered into a Loan and Security Agreement...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/maze-therapeutics-secures-new-200-million-loan-facility?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/maze-therapeutics-secures-new-200-million-loan-facility?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAZE","BK4007"],"gpt_icon":0},{"id":"2609319448","title":"Maze Therapeutics Inc Files for Mixed Shelf; Size Not Disclosed - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2609319448","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609319448?lang=en_us&edition=fundamental","pubTime":"2026-02-05 06:18","pubTimestamp":1770243510,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nFWN3Z015F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MAZE"],"gpt_icon":0},{"id":"2609319410","title":"Maze Therapeutics : Sales Agreement Prospectus Supplement Covering Offering of up to $200 Mln of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2609319410","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609319410?lang=en_us&edition=fundamental","pubTime":"2026-02-05 06:18","pubTimestamp":1770243510,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nFWN3Z015F:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MAZE"],"gpt_icon":0},{"id":"2609166563","title":"Maze Therapeutics Inc - Hercules Term Loan Facility up to $200 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2609166563","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609166563?lang=en_us&edition=fundamental","pubTime":"2026-02-05 05:46","pubTimestamp":1770241589,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nFWN3Z01I9:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MAZE"],"gpt_icon":0},{"id":"2609316668","title":"Maze Therapeutics Secures Up to $200 Million Term Loan Facility from Hercules Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2609316668","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609316668?lang=en_us&edition=fundamental","pubTime":"2026-02-05 05:46","pubTimestamp":1770241582,"startTime":"0","endTime":"0","summary":"Maze Therapeutics Inc. has entered into a new Loan and Security Agreement with Hercules Capital, Inc., establishing a senior secured term loan facility of up to $200 million. Under this agreement, an initial tranche of $40 million was funded on February 4, 2026, with up to six additional tranches totaling $160 million available, subject to certain milestones. The agreement includes customary covenants and events of default, and requires Maze Therapeutics to maintain minimum cash balances unless specific market capitalization thresholds are met. The agreement is designed to provide financial flexibility as the company advances its business objectives.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the or","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nNDL6tMcdl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4135","BK4007","HTGC"],"gpt_icon":0},{"id":"2609537315","title":"Maze Therapeutics President and CMO Harold Bernstein Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2609537315","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609537315?lang=en_us&edition=fundamental","pubTime":"2026-02-05 05:26","pubTimestamp":1770240379,"startTime":"0","endTime":"0","summary":"Harold Bernstein, President, R&D & Chief Medical Officer of Maze Therapeutics Inc., reported a disposal of common shares of Maze Therapeutics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 04, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nNDL2XPDBs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Maze Therapeutics President and CMO Harold Bernstein Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4007"],"gpt_icon":0},{"id":"2608075365","title":"Maze Therapeutics to Present at Guggenheim Emerging Outlook: Biotech Summit 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2608075365","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608075365?lang=en_us&edition=fundamental","pubTime":"2026-02-04 20:00","pubTimestamp":1770206450,"startTime":"0","endTime":"0","summary":"Maze Therapeutics Inc. will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026. Jason Coloma, Ph.D., chief executive officer of Maze Therapeutics, is scheduled to present at the event. A live webcast of the presentation will be available on the Investors section of the Maze Therapeutics website and will be archived for 60 days following the event.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on February 04, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nNDL1yNzdt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","BK4588","BK4112","IE00B3QW5Z07.USD","LU0314104364.USD","LU2095319765.USD","MAZE","NDAQ","BK4007","SG9999014021.USD","SG9999014039.USD","LU2210149790.SGD","SG9999014013.SGD","BK4585","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2210150020.SGD"],"gpt_icon":0},{"id":"2608848959","title":"Analysts Offer Insights on Healthcare Companies: Olema Pharmaceuticals (OLMA) and Maze Therapeutics, Inc. (MAZE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2608848959","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608848959?lang=en_us&edition=fundamental","pubTime":"2026-02-03 10:50","pubTimestamp":1770087016,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Olema Pharmaceuticals (OLMA – Research Report) and M...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-olema-pharmaceuticals-olma-and-maze-therapeutics-inc-maze-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-olema-pharmaceuticals-olma-and-maze-therapeutics-inc-maze-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029874061.USD","BK4581","BK4139","LU0128526141.USD","XBI","HCSG","XLV","MAZE","BK4137","BK4585","BK4588","LABU","BK4505","OLMA","BK4007"],"gpt_icon":0},{"id":"2608080890","title":"Maze Therapeutics CSBO Atul Dandekar Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2608080890","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608080890?lang=en_us&edition=fundamental","pubTime":"2026-02-03 05:22","pubTimestamp":1770067336,"startTime":"0","endTime":"0","summary":"Atul Dandekar, Chief Strategy and Business Officer of Maze Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 02, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nNDL4WhVf9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Maze Therapeutics CSBO Atul Dandekar Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4007"],"gpt_icon":0},{"id":"2606217744","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Maze Therapeutics, Inc. (MAZE), Adagene (ADAG) and Johnson & Johnson (JNJ)","url":"https://stock-news.laohu8.com/highlight/detail?id=2606217744","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606217744?lang=en_us&edition=fundamental","pubTime":"2026-01-26 20:20","pubTimestamp":1769430030,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Maze Therapeutics, Inc. (MAZE – Research Report), Adagene (ADAG –...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-maze-therapeutics-inc-maze-adagene-adag-and-johnson-johnson-jnj-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-maze-therapeutics-inc-maze-adagene-adag-and-johnson-johnson-jnj-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LU2592432038.USD","LU2129689514.USD","IE00B19Z3B42.SGD","LU1778281490.HKD","IE00BFXG1179.USD","JNJ","MAZE","XLV","LU1066051811.HKD","BK4534","BK4137","LU0345770308.USD","HCSG","IE00BKVL7J92.USD","XBI","BK4581","LU1935042991.SGD","IE00B2B36J28.USD","LU1057294990.SGD","LU1061106388.HKD","LU1066051498.USD","LU0795875169.SGD","LU0203347892.USD","LU1023059063.AUD","LU1059921491.USD","LU0912757837.SGD","IE00BVYPNV92.GBP","LU2750360641.GBP","SG9999001440.SGD","LU1221951046.USD","IE00BFTCPJ56.SGD","BK4139","LU1066053197.SGD","LU0345769631.USD","LU0058720904.USD","IE0009355771.USD","LU0203345920.USD","LU0345769128.USD","LU2750360997.AUD","LABU","LU1244550494.USD","BK4588","LU0234570918.USD","LU1674673428.USD","LU0689626769.HKD","LU0234572021.USD","IE00B42XCP33.USD","ADAG","LU0345770993.USD"],"gpt_icon":0},{"id":"2605810412","title":"Maze Therapeutics Inc : JP Morgan Raises Target Price to $52 From $42","url":"https://stock-news.laohu8.com/highlight/detail?id=2605810412","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605810412?lang=en_us&edition=fundamental","pubTime":"2026-01-21 20:39","pubTimestamp":1768999173,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nFWN3YM14Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MAZE","BK4007"],"gpt_icon":0},{"id":"2604913701","title":"Buy Rating on Maze Therapeutics: Attractive Risk‑Reward Driven by Differentiated APOL1 Kidney Disease Therapy MZE829 and Raised $46 Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2604913701","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604913701?lang=en_us&edition=fundamental","pubTime":"2026-01-20 01:38","pubTimestamp":1768844325,"startTime":"0","endTime":"0","summary":"Maze Therapeutics, Inc., the Healthcare sector company, was revisited by a Wall Street analyst on January 16. Analyst Julian Harrison from BTIG mai...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-on-maze-therapeutics-attractive-risk‑reward-driven-by-differentiated-apol1-kidney-disease-therapy-mze829-and-raised-46-target-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-on-maze-therapeutics-attractive-risk‑reward-driven-by-differentiated-apol1-kidney-disease-therapy-mze829-and-raised-46-target-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAZE"],"gpt_icon":0},{"id":"2604137145","title":"Maze Therapeutics price target raised to $46 from $37 at BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2604137145","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604137145?lang=en_us&edition=fundamental","pubTime":"2026-01-20 01:15","pubTimestamp":1768842907,"startTime":"0","endTime":"0","summary":"BTIG raised the firm’s price target on Maze Therapeutics (MAZE) to $46 from $37 and keeps a Buy rating on the shares. The firm believes the bar for...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maze-therapeutics-price-target-raised-to-46-from-37-at-btig-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maze-therapeutics-price-target-raised-to-46-from-37-at-btig-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAZE"],"gpt_icon":0},{"id":"2604915809","title":"Maze Therapeutics Showcases Pipeline Advancements in Kidney and Metabolic Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2604915809","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604915809?lang=en_us&edition=fundamental","pubTime":"2026-01-17 02:58","pubTimestamp":1768589914,"startTime":"0","endTime":"0","summary":"Maze Therapeutics Inc. has provided an update on its clinical pipeline focused on kidney and metabolic diseases. The company highlighted progress on its lead program, MZE829, a dual-mechanism APOL1 inhibitor developed as an oral therapy for APOL1-mediated kidney disease , a condition that disproportionately affects people of African ancestry. MZE829 has advanced to a Phase 2 clinical trial, with topline proof-of-concept data expected by the end of the first quarter of 2026. The Phase 1 data demonstrated a favorable safety profile, dose-proportional pharmacokinetics, and minimal drug-drug interaction risk, supporting the selection of a 250 mg once-daily dose for Phase 2. Additional pipeline programs include MZE782 for phenylketonuria , which is Phase 2 ready with trial initiation planned for mid-2026, and a chronic kidney disease program set to begin Phase 2 in the second half of 2026. The company reports an expected cash runway into 2028. You can access the full presentation through th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nNDL8jhJGp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MAZE"],"gpt_icon":0},{"id":"2604918276","title":"Maze Therapeutics Is Maintained at Buy by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2604918276","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604918276?lang=en_us&edition=fundamental","pubTime":"2026-01-17 01:35","pubTimestamp":1768584900,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MAZE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 16, 2026 12:35 ET (17:35 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE"],"gpt_icon":0},{"id":"2603924544","title":"Maze Therapeutics Showcases Pipeline Advancements in Kidney and Metabolic Disease Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2603924544","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603924544?lang=en_us&edition=fundamental","pubTime":"2026-01-13 00:07","pubTimestamp":1768234077,"startTime":"0","endTime":"0","summary":"Maze Therapeutics Inc. has provided an update on its pipeline focused on kidney and metabolic diseases. The company highlighted progress with its lead program, MZE829, a dual-mechanism APOL1 inhibitor in development for APOL1-mediated kidney disease , which disproportionately affects individuals of African ancestry. MZE829 is currently enrolling in a Phase 2 study, with topline proof-of-concept data expected by the end of Q1 2026. The candidate has demonstrated a favorable safety profile and predictable pharmacokinetics in Phase 1 studies, supporting the selection of a 250 mg once-daily dose for further evaluation. Additional programs in the pipeline include MZE782 for phenylketonuria , with plans to initiate Phase 2 trials by mid-2026, and a chronic kidney disease program expected to enter Phase 2 in the second half of 2026. Maze Therapeutics reports a cash runway extending into 2028 based on its current business plan. You can access the full presentation through the link below.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL6YYDpS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MAZE"],"gpt_icon":0},{"id":"2602010503","title":"Maze Therapeutics President, R&D & CMO Harold Bernstein Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2602010503","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602010503?lang=en_us&edition=fundamental","pubTime":"2026-01-10 05:52","pubTimestamp":1767995523,"startTime":"0","endTime":"0","summary":"Harold Bernstein, President, R&D & Chief Medical Officer of Maze Therapeutics Inc., reported a disposal of common shares of Maze Therapeutics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 09, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nNDL9FT0CK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Maze Therapeutics President, R&D & CMO Harold Bernstein Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MAZE"],"gpt_icon":0},{"id":"2602348531","title":"Maze Therapeutics Director Makes Major Insider Move With High-Value Stock Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2602348531","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602348531?lang=en_us&edition=fundamental","pubTime":"2026-01-09 10:03","pubTimestamp":1767924208,"startTime":"0","endTime":"0","summary":"New insider activity at Maze Therapeutics, Inc. ( ($MAZE) ) has taken place on January 8, 2026. Director Catherine Sohn has offloaded 29,413 shares...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/maze-therapeutics-director-makes-major-insider-move-with-high-value-stock-sale-insider-trading?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/maze-therapeutics-director-makes-major-insider-move-with-high-value-stock-sale-insider-trading?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","MAZE"],"gpt_icon":0},{"id":"2602138023","title":"Maze Therapeutics Director Catherine A. Sohn Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2602138023","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602138023?lang=en_us&edition=fundamental","pubTime":"2026-01-09 05:31","pubTimestamp":1767907884,"startTime":"0","endTime":"0","summary":"Catherine A. Sohn, Director at Maze Therapeutics Inc., has reported a disposal of common shares of the company, according to a recent SEC filing. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 08, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL4n8TtX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Maze Therapeutics Director Catherine A. Sohn Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MAZE"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":86,"code":"91000000","status":"200"}]}}